These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16144807)

  • 1. Computational methods for the design of effective therapies against drug resistant HIV strains.
    Beerenwinkel N; Sing T; Lengauer T; Rahnenführer J; Roomp K; Savenkov I; Fischer R; Hoffmann D; Selbig J; Korn K; Walter H; Berg T; Braun P; Fätkenheuer G; Oette M; Rockstroh J; Kupfer B; Kaiser R; Däumer M
    Bioinformatics; 2005 Nov; 21(21):3943-50. PubMed ID: 16144807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioinformatics approach to predicting HIV drug resistance.
    Cordes F; Kaiser R; Selbig J
    Expert Rev Mol Diagn; 2006 Mar; 6(2):207-15. PubMed ID: 16512780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy.
    Wang D; Larder B; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; D'Arminio Monforte A; Torti C; Zazzi M; Lane C
    Artif Intell Med; 2009 Sep; 47(1):63-74. PubMed ID: 19524413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-resistant human immunodefiency virus.
    Kozal MJ
    Clin Microbiol Infect; 2009 Jan; 15 Suppl 1():69-73. PubMed ID: 19220361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of artificial neural networks to predict virological response to combination HIV therapy.
    Larder B; Wang D; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; Monforte AD; Torti C; Zazzi M; Lane C
    Antivir Ther; 2007; 12(1):15-24. PubMed ID: 17503743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination against drug resistance in HIV infection.
    Boberg A; Isaguliants M
    Expert Rev Vaccines; 2008 Feb; 7(1):131-45. PubMed ID: 18251699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A game theoretical approach to optimal control of dual drug delivery for HIV infection treatment.
    Wu J; Zhang M
    IEEE Trans Syst Man Cybern B Cybern; 2010 Jun; 40(3):694-702. PubMed ID: 20176541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When to initiate HIV therapy: a control theoretic approach.
    Jeffrey AM; Xia X; Craig IK
    IEEE Trans Biomed Eng; 2003 Nov; 50(11):1213-20. PubMed ID: 14619991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation and control of the human immunodeficiency virus.
    Stengel RF
    Math Biosci; 2008 Jun; 213(2):93-102. PubMed ID: 18439629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan.
    Chang SY; Chen MY; Lee CN; Sun HY; Ko W; Chang SF; Chang KL; Hsieh SM; Sheng WH; Liu WC; Wu CH; Kao CL; Hung CC; Chang SC
    J Antimicrob Chemother; 2008 Mar; 61(3):689-93. PubMed ID: 18227088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs.
    Perno CF; Moyle G; Tsoukas C; Ratanasuwan W; Gatell J; Schechter M
    J Med Virol; 2008 Apr; 80(4):565-76. PubMed ID: 18297706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of HAART with genetic algorithms and agent-based models of HIV infection.
    Castiglione F; Pappalardo F; Bernaschi M; Motta S
    Bioinformatics; 2007 Dec; 23(24):3350-5. PubMed ID: 17942443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of the human immunodeficiency virus featuring laboratory testing for drug resistance.
    Scosyrev E
    Clin Lab Sci; 2006; 19(4):231-45; quiz 246-9. PubMed ID: 17181129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.
    Metzner KJ; Allers K; Rauch P; Harrer T
    AIDS; 2007 Mar; 21(6):703-11. PubMed ID: 17413691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized structured treatment interruption for HIV therapy and its performance analysis on controllability.
    Ko JH; Kim WH; Chung CC
    IEEE Trans Biomed Eng; 2006 Mar; 53(3):380-6. PubMed ID: 16532764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug resistance in HIV infection].
    Asjö B; Langeland N
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2593-6. PubMed ID: 19023373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of HIV-1 drug resistance during antiretroviral treatment.
    Rong L; Feng Z; Perelson AS
    Bull Math Biol; 2007 Aug; 69(6):2027-60. PubMed ID: 17450401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of the HIV-suppressive chemokines CCL3/MIP-1alpha and CCL22/MDC is associated with more effective antiretroviral therapy in HIV-infected children.
    Lambert JS; Machado ES; Watson DC; Sill AM; Lim JK; Charurat M; Cunha SM; Afonso AO; Oliviera RH; Tanuri A; DeVico AL
    Pediatr Infect Dis J; 2007 Oct; 26(10):935-44. PubMed ID: 17901800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection.
    Booth CL; Geretti AM
    J Antimicrob Chemother; 2007 Jun; 59(6):1047-56. PubMed ID: 17449483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.